Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID‐19 era
- 22 May 2020
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (4), e13499
- https://doi.org/10.1111/dth.13499
Abstract
Click on the article title to read more.Keywords
This publication has 9 references indexed in Scilit:
- Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL ‐6 in COVID ‐19 outbreakDermatologic Therapy, 2020
- Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquineDermatologic Therapy, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- COVID‐19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for actionDermatologic Therapy, 2020
- Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatologyNature Reviews Rheumatology, 2020
- Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV Reactivation2019
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune SystemInternational Journal of Molecular Sciences, 2017
- Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: An immunohistochemical studyThe Journal of Allergy and Clinical Immunology: In Practice, 2016
- Drug reaction with eosinophilia and systemic symptoms caused by lenalidomideEuropean Journal of Dermatology, 2012